Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This study has two phases, a dose escalation phase and a dose expansion phase. For dose
escalation, the primary objective is to estimate the maximum tolerated dose of AEB071 in
patients with diffuse large b-cell lymphoma. The endpoint for this objective will be
occurrence of Dose Limiting Toxicity. For dose expansion, the primary objective is to
characterize the safety and tolerability of the maximum tolerated dose or recommended phase 2
dose of AEB071 in patients with diffuse large b-cell lymphoma. The endpoints for this
objective will be occurrence of Adverse Events (AEs), Serious Adverse Events (SAEs),
assessment of clinical laboratory values, and vital sign measurements.